Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-10-10Clinical Trial Update: Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors [Phase 2]
Phase 2 trial evaluating rigosertib plus pembrolizumab in unresectable/metastatic melanoma refractory to PD-1 inhibitors; the study is curre…
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma [Phase 2]
Phase II trial evaluating adding tocilizumab to ipilimumab and nivolumab for unresectable stage III/IV melanoma. Results were posted on 2024…
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) [Phase 2]
A Phase 2 study evaluating the efficacy and safety of combining lenvatinib with pembrolizumab in patients with advanced melanoma previously …
-
CLINICAL_TRIALS trial_result · 2024-10-08Clinical Trial Update: CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma [Phase 2]
A Phase 2 clinical trial evaluating a combination of CD8+ antigen-specific T cells with cyclophosphamide, aldesleukin, and ipilimumab for me…
-
CLINICAL_TRIALS trial_result · 2024-10-08Clinical Trial Update: Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma [Phase 1, Phase 2]
Phase 1/2 study evaluating autologous genetically modified lymphocytes followed by Aldesleukin in patients with stage III or metastatic mela…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-10-08Clinical Trial Update: Safety and Avoidance of Futile Excisions Through Skin Tele-triage
Completed clinical trial evaluating skin tele-triage to reduce futile excisions for melanoma, with aims to improve safety and resource use.
-
CLINICAL_TRIALS trial_result · 2024-10-03Clinical Trial Update: A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma [Phase 1]
Phase 1 study evaluating the safety and therapeutic activity of RO6874281 in combination with pembrolizumab for advanced or metastatic melan…
-
CLINICAL_TRIALS trial_result · 2024-10-02Clinical Trial Update: Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma [Phase 2]
A Phase 2 trial evaluating an anti-PD-1 antibody in combination with high-dose interleukin-2 for metastatic melanoma has been terminated, wi…
-
CLINICAL_TRIALS trial_result · 2024-09-27Clinical Trial Update: Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors [Phase 1]
Phase 1 pharmacokinetic drug-drug interaction study evaluating encorafenib and binimetinib on probe drugs in patients with BRAF V600-mutant …
-
CLINICAL_TRIALS trial_result · 2024-09-25Clinical Trial Update: Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting [Phase 2]
Phase 2 trial evaluating the combination of nivolumab and relatlimab in metastatic melanoma patients who have not received prior immunothera…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Hydrochlorothiazide and Risk of Skin Cancer
A completed CNODES study evaluating whether hydrochlorothiazide is associated with an increased risk of skin cancers, including non-melanoma…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma [Phase 3]
A Phase III randomized trial comparing the PD-1 inhibitor JS001 (toripalimab) to dacarbazine as first-line therapy for unresectable or metas…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations [Phase 1]
Phase 1 bioequivalence study comparing Binimetinib 3 x 15 mg formulation with a 45 mg formulation in melanoma patients with BRAF V600 mutati…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: PVSRIPO for Patients With Unresectable Melanoma [Phase 1]
Phase 1 trial of PVSRIPO for unresectable melanoma has been terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1
A completed clinical trial evaluating the combination of lenvatinib with an anti-PD1 therapy for metastatic melanoma has finished.
-
CLINICAL_TRIALS trial_result · 2024-09-05Clinical Trial Update: How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
This clinical trial update discusses how gut microbes and metabolism may predict responses to skin cancer immunotherapy, though the study ha…
-
CLINICAL_TRIALS trial_result · 2024-09-04Clinical Trial Update: Utility of Novel BRAF Test for Melanoma
A clinical trial evaluating a novel BRAF test for melanoma has completed and posted results. Results were posted on 2024-09-04.
-
CLINICAL_TRIALS trial_result · 2024-08-27Clinical Trial Update: Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma [Phase 2]
Phase 2 trial evaluating Talimogene laherparepvec (Imlygic) in combination with pembrolizumab for advanced or unresectable melanoma, with re…
-
CLINICAL_TRIALS trial_result · 2024-08-27Clinical Trial Update: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery [Phase 3]
A Phase 3 trial comparing high-dose recombinant interferon alfa-2B or ipilimumab to pembrolizumab in patients with surgically removed stage …
-
CLINICAL_TRIALS trial_result · 2024-08-23Clinical Trial Update: Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma [Phase 2]
Phase 2 trial evaluating the safety and efficacy of selinexor in combination with pembrolizumab for recurrent advanced melanoma; the study h…
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma [Phase 2]
Phase 2 trial evaluating dabrafenib and trametinib with or without hydroxychloroquine in stage IIIC or IV BRAF V600E/K melanoma; the study w…
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma [Phase 2]
Phase 2 clinical trial update evaluating ipilimumab and nivolumab followed by adjuvant nivolumab in locally advanced or limited metastatic m…
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors [Phase 1]
Phase 1 study evaluating the combination of everolimus and vatalanib in patients with advanced solid tumors, including several neuroendocrin…
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF) [Phase 1]
Phase 1 trial of autologous, lethally irradiated melanoma cells engineered by adenoviral gene transfer to secrete GM-CSF; the study has comp…
-
CLINICAL_TRIALS trial_result · 2024-08-16Clinical Trial Update: Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma
The clinical trial update reports relapse-free survival results for adjuvant dabrafenib/trametinib in patients with BRAF V600-mutated stage …